Kazia Therapeutics : Appointment of Director Form 6 K

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2024

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant's name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Appointment of Director

Resignation of Principal Financial and Accounting Officer; Appointment of Principal Accounting Officer and Principal Financial Officer

On May 16, 2024, Kazia Therapeutics Limited (the "Company") received notice from Gabrielle Heaton of her intention to resign as the Company's Vice President, Finance and Administration, effective June 28, 2024. Ms. Heaton's resignation is not the result of any disagreement between Ms. Heaton and the Company, its management or board of directors, or related to the Company's operations, policies or practices.

On June 24, 2024, the Company's Board of Directors appointed Jeffrey Bonacorda as its Principal Accounting Officer and Principal Financial Officer, effective July 1, 2024. Mr. Bonacorda's annual base compensation will be $150,000.

Mr. Bonacorda joined Kazia on May 13, 2024 and currently serves as the Company's Vice President, Finance and Controller. Mr Bonacorda is a senior accounting professional with more than 25 years of experience in the commercial pharmaceutical, consumer products and service industries.

The Company hereby incorporates by reference the information contained herein into the Company's registration statements on Form F-3 (File Nos. 333-259224 and 333-276091).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

John Friend

Chief Executive Officer

Date: 24 June 2024